Accuracy of faecal calprotectin and neutrophil gelatinase B-associated lipocalin in evaluating subclinical inflammation in ulcerative colitis-the ACERTIVE study

Journal of Crohn's and Colitis

Volumn 11, Issue 4, 2017, Pages 435-444

  Magro, Fernando ^a,b,c   Lopes, Susana ^a   Coelho, Rosa ^a   Cotter, José ^d   de Castro, Francisca Dias ^d   de Sousa, Helena Tavares ^e,f   Salgado, Marta ^g   Andrade, Patrícia ^a   Vieira, Ana Isabel ^h   Figueiredo, Pedro ^h   Caldeira, Paulo ^e   Sousa, A ^e   Duarte, Maria A ⁱ   Ávila, Filipa ⁱ   Silva, João ^j   Moleiro, Joana ^j   Mendes, Sofia ^k   Giestas, Sílvia ^k   Ministro, Paula ^l   Sousa, Paula ^l   Gonçalves, Raquel ^m   Gonçalves, Bruno ^m   Oliveira, Ana ⁿ   Chagas, Cristina ^o   Torres, Joana ^p   Dias, Cláudia Camila ^b,c   Lopes, Joanne ^a   Borralho, Paula ^q   Afonso, Joana ^b,c   Geboes, Karel ^r   Carneiro, Fátima ^a,c   more..

^a Centro Hospitalar Universitário de São João   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d Hospital da Senhora da Oliveira   (Portugal)

^e HOSPITAL DE FARO   (Portugal)

^f UNIVERSITY OF ALGARVE   (Portugal)

^g HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^h HOSPITAL GARCIA DE ORTA   (Portugal)

ⁱ HOSPITAL DO DIVINO ESPÍRITO SANTO   (Portugal)

^j INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^k CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^l Centro Hospitalar Tondela Viseu ^*  (Portugal)

^m HOSPITAL DE BRAGA   (Portugal)

ⁿ HOSPITAL FERNANDO FONSECA   (Portugal)

^o Centro Hospitalar Lisboa Ocidental   (Portugal)

^p Interventional Pulmonology Section   (Portugal)

^q INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^r UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Endoscopic and histological remission; Faecal markers; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CALGRANULIN; IRON BINDING PROTEIN; MESALAZINE; NEUTROPHIL GELATINASE B ASSOCIATED LIPOCALIN; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG HYPERSENSITIVITY; FECES ANALYSIS; FECES LEVEL; FEMALE; GEBOES INDEX; HEALING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INTESTINE ENDOSCOPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLASMACYTOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REMISSION; ULCERATIVE COLITIS; ULCERATIVE COLITIS ENDOSCOPIC INDEX OF SEVERITY; CHEMISTRY; CLINICAL TRIAL; COLON; FECES; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOLOGY;

ADULT; COLITIS, ULCERATIVE; COLON; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; LIPOCALIN-2; MALE; MIDDLE AGED; NEUTROPHILS;

EID: 85010891538     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw170     Document Type: Article

References (37)

1. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5A-36A.
2. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-90.
3. Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22.
4. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
5. Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014;8:1582-97.
6. Vatn MH. Mucosal healing: impact on the natural course or therapeutic strategies. Dig Dis 2009;27:470-5.
7. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9.
8. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-8.
9. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099-105; quiz 340-1.
10. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-9.
11. Marchal Bressenot A, Riddell RH, Boulagnon-Rombi C, et al. Review article: the histological assessment of disease activity in ulcerative colitis. Aliment Pharmacol Ther 2015;42:957-67.
12. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-13.
13. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-6.
14. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012;18:1894-9.
15. Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008;40:547-53.
16. Oikonomou KA, Kapsoritakis AN, Theodoridou C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol 2012;47:519-30.
17. Yesil A, Gönen C, Senates E, et al. Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. Dig Dis Sci 2013;58:2587-93.
18. de Bruyn M, Arijs I, De Hertogh G, et al. Serum neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate marker for mucosal healing in patients with Crohn's disease. J Crohns Colitis 2015;9:1079-87.
19. de Bruyn M, Arijs I, Wollants WJ, et al. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2014;20:1198-207.
20. Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999;94:2923-8.
21. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS). Gut 2012;61:535-42.
22. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New Engl J Med 1987;317:1625-9.
23. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324-38.
24. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012;107:1684-92.
25. Driman DK, Preiksaitis HG. Colorectal inflammation and increased cell proliferation associated with oral sodium phosphate bowel preparation solution. Human Pathol 1998;29:972-8.
26. Bucher P, Gervaz P, Egger JF, Soravia C, Morel P. Morphologic alterations associated with mechanical bowel preparation before elective colorectal surgery: a randomized trial. Dis Colon Rectum 2006;49:109-12.
27. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
28. Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol 2016;9:21-9.
29. Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol 2015;8:23-36.
30. Kim DB, Lee KM, Lee JM, et al. Correlation between histological activity and endoscopic, clinical, and serologic activities in patients with ulcerative colitis. Gastroenterol Res Pract 2016;2016:5832051.
31. Zenlea T, Yee EU, Rosenberg L, et al. Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study. Am J Gastroenterol 2016;111:685-90.
32. Guardiola J, Lobaton T, Rodriguez-Alonso L, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol 2014;12:1865-70.
33. Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Fecal lactoferrin, calprotectin, PMN-elastase, CRP and white blood cell count as an indicator for mucosal healing and clinical course of disease in patients with mild to moderate ulcerative colitis: post hoc analysis of a prospective clinical trial. J Crohns Colitis 2016;10:786-94.
34. Yamaguchi S, Takeuchi Y, Arai K, et al. Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol 2016;31:93-8.
35. Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut 2015, published online Oct 16 DOI: 10.1136/ gutjnl-2015-310393
36. Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. Gut 2015, published online Oct 13 DOI: 10.1136/gutjnl-2015-310187
37. De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013;19:2111-7.